Effects of N-acetylcysteine on dense cell formation in sickle cell disease

Betty Sue Pace, Archil Shartava, Ardie Pack-Mabien, Mudhari Mulekar, Alfredo Ardia, Steven R. Goodman

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The extent to which dense and irreversible sickle cells (ISCs) contribute to vaso-occlusive episodes in sickle cell disease remains unclear. N-Acetylcysteine (NAC) inhibits dense cell and ISC formation in sickle erythrocytes in vitro and restores glutathione levels toward normal. A phase II double-blind randomized clinical trial was completed to determine the efficacy of NAC in decreasing dense cell and ISC formation, and vaso-occlusive episodes in sickle cell disease. Twenty-one subjects with a history of at least two vaso-occlusive episodes per year and 6% dense cells were enrolled. Four treatment groups were analyzed; NAC at a dose of 2,400 mg per day decreased the percent dense cells from 20.1 ± 2.9 to 12.6 ± 2.1 (P < 0.05) and increased red cell glutathione levels from 292.8 ± 74.5 to 576.7 ± 155.1 (P < 0.05). In addition, we observed a decrease in vaso-occlusive episodes from 0.03 to 0.006 episodes per person-days and a decreased in relative risk to R = 0.39. Although NAC did not significantly decrease the number of ISCs, there was a downward trend at all doses tested. In summary, NAC inhibited dense cell formation, restored glutathione levels toward normal, and decreased vaso-occlusive episodes at a well-tolerated dose of 2,400 mg per day. To determine the long-term efficacy and safety of NAC, a multicenter phase III clinical trial is required.

Original languageEnglish (US)
Pages (from-to)26-32
Number of pages7
JournalAmerican Journal of Hematology
Volume73
Issue number1
DOIs
StatePublished - May 1 2003

Fingerprint

Acetylcysteine
Sickle Cell Anemia
Glutathione
Phase III Clinical Trials
Randomized Controlled Trials
Erythrocytes
Safety

Keywords

  • Dense cells
  • Glutathione
  • N-acetylcysteine
  • Sickle cell disease
  • Vaso-occlusive episodes

ASJC Scopus subject areas

  • Hematology

Cite this

Pace, B. S., Shartava, A., Pack-Mabien, A., Mulekar, M., Ardia, A., & Goodman, S. R. (2003). Effects of N-acetylcysteine on dense cell formation in sickle cell disease. American Journal of Hematology, 73(1), 26-32. https://doi.org/10.1002/ajh.10321

Effects of N-acetylcysteine on dense cell formation in sickle cell disease. / Pace, Betty Sue; Shartava, Archil; Pack-Mabien, Ardie; Mulekar, Mudhari; Ardia, Alfredo; Goodman, Steven R.

In: American Journal of Hematology, Vol. 73, No. 1, 01.05.2003, p. 26-32.

Research output: Contribution to journalArticle

Pace, BS, Shartava, A, Pack-Mabien, A, Mulekar, M, Ardia, A & Goodman, SR 2003, 'Effects of N-acetylcysteine on dense cell formation in sickle cell disease', American Journal of Hematology, vol. 73, no. 1, pp. 26-32. https://doi.org/10.1002/ajh.10321
Pace, Betty Sue ; Shartava, Archil ; Pack-Mabien, Ardie ; Mulekar, Mudhari ; Ardia, Alfredo ; Goodman, Steven R. / Effects of N-acetylcysteine on dense cell formation in sickle cell disease. In: American Journal of Hematology. 2003 ; Vol. 73, No. 1. pp. 26-32.
@article{2d464f41277f454bb32b1cd30b6efa35,
title = "Effects of N-acetylcysteine on dense cell formation in sickle cell disease",
abstract = "The extent to which dense and irreversible sickle cells (ISCs) contribute to vaso-occlusive episodes in sickle cell disease remains unclear. N-Acetylcysteine (NAC) inhibits dense cell and ISC formation in sickle erythrocytes in vitro and restores glutathione levels toward normal. A phase II double-blind randomized clinical trial was completed to determine the efficacy of NAC in decreasing dense cell and ISC formation, and vaso-occlusive episodes in sickle cell disease. Twenty-one subjects with a history of at least two vaso-occlusive episodes per year and 6{\%} dense cells were enrolled. Four treatment groups were analyzed; NAC at a dose of 2,400 mg per day decreased the percent dense cells from 20.1 ± 2.9 to 12.6 ± 2.1 (P < 0.05) and increased red cell glutathione levels from 292.8 ± 74.5 to 576.7 ± 155.1 (P < 0.05). In addition, we observed a decrease in vaso-occlusive episodes from 0.03 to 0.006 episodes per person-days and a decreased in relative risk to R = 0.39. Although NAC did not significantly decrease the number of ISCs, there was a downward trend at all doses tested. In summary, NAC inhibited dense cell formation, restored glutathione levels toward normal, and decreased vaso-occlusive episodes at a well-tolerated dose of 2,400 mg per day. To determine the long-term efficacy and safety of NAC, a multicenter phase III clinical trial is required.",
keywords = "Dense cells, Glutathione, N-acetylcysteine, Sickle cell disease, Vaso-occlusive episodes",
author = "Pace, {Betty Sue} and Archil Shartava and Ardie Pack-Mabien and Mudhari Mulekar and Alfredo Ardia and Goodman, {Steven R.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1002/ajh.10321",
language = "English (US)",
volume = "73",
pages = "26--32",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Effects of N-acetylcysteine on dense cell formation in sickle cell disease

AU - Pace, Betty Sue

AU - Shartava, Archil

AU - Pack-Mabien, Ardie

AU - Mulekar, Mudhari

AU - Ardia, Alfredo

AU - Goodman, Steven R.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - The extent to which dense and irreversible sickle cells (ISCs) contribute to vaso-occlusive episodes in sickle cell disease remains unclear. N-Acetylcysteine (NAC) inhibits dense cell and ISC formation in sickle erythrocytes in vitro and restores glutathione levels toward normal. A phase II double-blind randomized clinical trial was completed to determine the efficacy of NAC in decreasing dense cell and ISC formation, and vaso-occlusive episodes in sickle cell disease. Twenty-one subjects with a history of at least two vaso-occlusive episodes per year and 6% dense cells were enrolled. Four treatment groups were analyzed; NAC at a dose of 2,400 mg per day decreased the percent dense cells from 20.1 ± 2.9 to 12.6 ± 2.1 (P < 0.05) and increased red cell glutathione levels from 292.8 ± 74.5 to 576.7 ± 155.1 (P < 0.05). In addition, we observed a decrease in vaso-occlusive episodes from 0.03 to 0.006 episodes per person-days and a decreased in relative risk to R = 0.39. Although NAC did not significantly decrease the number of ISCs, there was a downward trend at all doses tested. In summary, NAC inhibited dense cell formation, restored glutathione levels toward normal, and decreased vaso-occlusive episodes at a well-tolerated dose of 2,400 mg per day. To determine the long-term efficacy and safety of NAC, a multicenter phase III clinical trial is required.

AB - The extent to which dense and irreversible sickle cells (ISCs) contribute to vaso-occlusive episodes in sickle cell disease remains unclear. N-Acetylcysteine (NAC) inhibits dense cell and ISC formation in sickle erythrocytes in vitro and restores glutathione levels toward normal. A phase II double-blind randomized clinical trial was completed to determine the efficacy of NAC in decreasing dense cell and ISC formation, and vaso-occlusive episodes in sickle cell disease. Twenty-one subjects with a history of at least two vaso-occlusive episodes per year and 6% dense cells were enrolled. Four treatment groups were analyzed; NAC at a dose of 2,400 mg per day decreased the percent dense cells from 20.1 ± 2.9 to 12.6 ± 2.1 (P < 0.05) and increased red cell glutathione levels from 292.8 ± 74.5 to 576.7 ± 155.1 (P < 0.05). In addition, we observed a decrease in vaso-occlusive episodes from 0.03 to 0.006 episodes per person-days and a decreased in relative risk to R = 0.39. Although NAC did not significantly decrease the number of ISCs, there was a downward trend at all doses tested. In summary, NAC inhibited dense cell formation, restored glutathione levels toward normal, and decreased vaso-occlusive episodes at a well-tolerated dose of 2,400 mg per day. To determine the long-term efficacy and safety of NAC, a multicenter phase III clinical trial is required.

KW - Dense cells

KW - Glutathione

KW - N-acetylcysteine

KW - Sickle cell disease

KW - Vaso-occlusive episodes

UR - http://www.scopus.com/inward/record.url?scp=0242600642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242600642&partnerID=8YFLogxK

U2 - 10.1002/ajh.10321

DO - 10.1002/ajh.10321

M3 - Article

C2 - 12701116

AN - SCOPUS:0242600642

VL - 73

SP - 26

EP - 32

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -